We didn’t start this walk yesterday.

Many of our leaders have worked together for more than 210 dog years, at some of the world’s largest pharmaceutical companies.

During those years we learned some important lessons the hard way. Like how important it is to match new products with true needs in the marketplace. And that making large investments before early stage clinical evaluation is a sure-fire way to end up in the doghouse.*

Today we know how to keep the process, and products, moving at the speed of a hyped-up puppy.

*85% of the products we placed in development ultimately achieved regulatory approval.
With this much experience, it’s hard to trip us up.

Our team has developed, launched, or marketed more than 20 companion animal products in the veterinary industry for dogs, cats, and horses.

Many of these products—like SENTINEL® (milbemycin oxime/lufenuron), PERCORTEN-V® (DOCP), and CLARO® (florfenicol, terbinafine, mometasone furoate)—became category leading top-selling products.

You’ll purr when you see the list of key milestones in the veterinary industry we’ve been a part of. We have more firsts than a cat has lives. To learn more click here.

If you want a proven track record, we have it in spades.

SENTINEL is a registered trademark of Merck.
CLARO and PERCORTEN-V are registered trademarks of Elanco.

When you innovate, a ball of yarn
is way more than just a ball of yarn.

It’s not enough to rest on laurels. That’s why we have been issued 47 patents, and have an additional 60 pending worldwide. In fact, we’ve introduced innovations across almost the entire spectrum of companion animal medicine—and touched nearly every product and treatment category.

Our entire team is constantly evaluating the marketplace for opportunities to fulfill unmet needs, even ones that pet owners and veterinarians don’t realize they have.

We’re currently focusing on veterinarian-administered single-treatment products--such as CLARO® (florfenicol, terbinafine, mometasone furoate) Otic Suspension for the treatment of otitis externa in dogs--that help ensure improved health for pets, while reducing pet-owner compliance concerns.

Easy treatments. Healthy pets. Happy owners. Hero veterinarians. Successful products. It’s a formula that works.

If you want to catch the prize,
you have to stay focused.

Understanding why people love their companion animals is easy. Getting new or improved FDA-pharmaceuticals to market is not.

At Piedmont Animal Health we know a thing or two about streamlining the process, so nobody is stuck chasing their tail. In fact, we’ve been known to get products to market nearly 40% faster than the average time.*

Using human resource efficiencies—and hiring only the best team members—means we can remain an incredibly sleek organization, helping us stay flexible, so we can quickly adjust to changing market trends.

* Based on a review of recent FDA NADA approvals, it takes an average of 9 to 10 years to bring a new FDA animal drug to market. Piedmont has accomplished this in 6 years.
We’re churning out new products
faster than you can hide a treat.

Piedmont Animal Health currently has more than 20 products in various stages of development, and has received approval on a total of seven new and generic products for dogs and cats from FDA since 2013 - an industry leading achievement.

We plan to license or commercialize more than 10 of the products in our current portfolio, and hold out-licensing agreements with major global pharmaceutical companies for the others.

Based on independent market research*, sales of our retained portfolio products are projected to reach $200 million annually.

* Based on independent new product research conducted by AllPoints Research with 316 veterinary practices in November/December 2014.